SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020

SMi Group 15 - 16 January 2020, London, UK.
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London. As Europe's leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year's programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director - Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products, Senior Pharmaceutical Assessor and many more.

Benefits of attending

  • Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design
  • Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices
  • Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery
  • Assess industry case studies exploring how to overcome challenges of extractables and leachables

Chairs for 2019

  • James Mellman, Device Manager, Novartis
  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured speakers

  • Abha Raveau-Violette, Device Manager, AstraZeneca
  • Amanda Matthews, Senior Director, Pfizer
  • Anil-Kumar Busimi, Strategy and Innovation, Senior Global Product Manager, SCHOTT
  • Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Cedric Gysel, Healthcare Solutions Manager, Johnson & Johnson
  • Cinzia Rotella, Senior Materials Scientist, Sanofi
  • Clemens Guenther, Director Nonclinical Safety Consumer Care, Bayer
  • Colin Roscoe, Principal Human Factors Scientist, Teva Pharmaceuticals
  • Hiroki Hasegawa, Researcher, Mitsubishi Gas Chemical Company, Inc
  • James Mellman, Device Manager, Novartis A G
  • Kewei Yang, Pharmaceutical Scientist, Roche
  • Khaudeja Bano, Head of Medical Devices, Abbott Molecular Inc
  • Marion Westwood, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)
  • Matthew Nicolas, Investigator, GlaxoSmithKline
  • Nicolas Eon, Senior Global Product Manager, SCHOTT
  • Olaf Lebau, Design Engineer for Medical Devices and Combination Products, Boehringer Ingelheim GmbH
  • Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals
  • Remy Vomscheid, Director, Devices Development & Technologies, IPSEN Pharmsciences
  • Torsten Kneuss, Quality Assurance Manager Combination Products, Bayer Pharma

Plus, pre-conference workshop day will be taking place on 14th January in London:

Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards
Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH
Workshop C: Extractables and Leachables: Considerations for PFS Platforms

For more information and to register, please visit:
http://www.pre-filled-syringes.com/wpnwl

Early-Bird Rates

  • Register by 29th November to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...